Biosynex
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hyg… Read more
Biosynex (ALBIO) - Net Assets
Latest net assets as of June 2025: €44.31 Million EUR
Based on the latest financial reports, Biosynex (ALBIO) has net assets worth €44.31 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€149.44 Million) and total liabilities (€105.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €44.31 Million |
| % of Total Assets | 29.65% |
| Annual Growth Rate | N/A |
| 5-Year Change | 21.43% |
| 10-Year Change | 280.93% |
| Growth Volatility | 1036.26 |
Biosynex - Net Assets Trend (2006–2024)
This chart illustrates how Biosynex's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biosynex (2006–2024)
The table below shows the annual net assets of Biosynex from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €80.50 Million | -35.25% |
| 2023-12-31 | €124.31 Million | -25.45% |
| 2022-12-31 | €166.76 Million | -0.62% |
| 2021-12-31 | €167.81 Million | +153.14% |
| 2020-12-31 | €66.29 Million | +118.21% |
| 2019-12-31 | €30.38 Million | +3.81% |
| 2018-12-31 | €29.26 Million | +1.23% |
| 2017-12-31 | €28.91 Million | +18.65% |
| 2016-12-31 | €24.36 Million | +15.30% |
| 2015-12-31 | €21.13 Million | +512.55% |
| 2014-12-31 | €3.45 Million | -12.80% |
| 2013-12-31 | €3.96 Million | -23.58% |
| 2012-12-31 | €5.18 Million | +0.27% |
| 2011-12-31 | €5.16 Million | +4044.19% |
| 2010-12-31 | €124.59K | +136.48% |
| 2009-12-31 | €-341.55K | -122.16% |
| 2008-12-31 | €-153.74K | -27.05% |
| 2007-12-31 | €-121.00K | -3933.33% |
| 2006-12-31 | €-3.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biosynex's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7437148300.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €73.80 Million | 91.59% |
| Common Stock | €1.08 Million | 1.34% |
| Other Comprehensive Income | €-19.90 Million | -24.69% |
| Other Components | €25.60 Million | 31.77% |
| Total Equity | €80.58 Million | 100.00% |
Biosynex Competitors by Market Cap
The table below lists competitors of Biosynex ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xintela AB
ST:XINT
|
$7.06 Million |
|
Sintex Plastics Technology Limited
NSE:SPTL
|
$7.07 Million |
|
ASM INT (AVS.SG)
STU:AVS
|
$7.07 Million |
|
Bd Multimedia
PA:ALBDM
|
$7.07 Million |
|
Buana Listya Tama Tbk PT
JK:BULL
|
$7.06 Million |
|
Tek Seng Holdings Bhd
KLSE:7200
|
$7.06 Million |
|
Planet Green Holdings Corp
NYSE MKT:PLAG
|
$7.06 Million |
|
Planet Image International Limited Class A Ordinary Shares
NASDAQ:YIBO
|
$7.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biosynex's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 124,480,000 to 80,576,000, a change of -43,904,000 (-35.3%).
- Net loss of 43,300,000 reduced equity.
- Other comprehensive income decreased equity by 62,392,000.
- Other factors increased equity by 61,788,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-43.30 Million | -53.74% |
| Other Comprehensive Income | €-62.39 Million | -77.43% |
| Other Changes | €61.79 Million | +76.68% |
| Total Change | €- | -35.27% |
Book Value vs Market Value Analysis
This analysis compares Biosynex's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.14x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | €-0.15 | €0.85 | x |
| 2009-12-31 | €-0.32 | €0.85 | x |
| 2010-12-31 | €0.12 | €0.85 | x |
| 2011-12-31 | €4.77 | €0.85 | x |
| 2012-12-31 | €4.38 | €0.85 | x |
| 2013-12-31 | €3.16 | €0.85 | x |
| 2014-12-31 | €2.15 | €0.85 | x |
| 2015-12-31 | €3.42 | €0.85 | x |
| 2016-12-31 | €3.03 | €0.85 | x |
| 2017-12-31 | €3.16 | €0.85 | x |
| 2018-12-31 | €3.20 | €0.85 | x |
| 2019-12-31 | €3.33 | €0.85 | x |
| 2020-12-31 | €6.44 | €0.85 | x |
| 2021-12-31 | €16.15 | €0.85 | x |
| 2022-12-31 | €15.81 | €0.85 | x |
| 2023-12-31 | €9.60 | €0.85 | x |
| 2024-12-31 | €6.18 | €0.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biosynex utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -53.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.79%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 2.42x
- Recent ROE (-53.74%) is below the historical average (-5.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 0.00% | -33.44% | 0.84x | 0.00x | €-146.62K |
| 2009 | 0.00% | -32.60% | 1.10x | 0.00x | €-190.41K |
| 2010 | -23.17% | -2.87% | 0.94x | 8.57x | €-41.33K |
| 2011 | -6.32% | -31.08% | 0.17x | 1.18x | €-842.81K |
| 2012 | -13.95% | -47.13% | 0.17x | 1.71x | €-1.24 Million |
| 2013 | -44.45% | -96.51% | 0.25x | 1.85x | €-2.15 Million |
| 2014 | -44.34% | -35.08% | 0.64x | 1.97x | €-1.87 Million |
| 2015 | -1.72% | -3.58% | 0.36x | 1.32x | €-2.48 Million |
| 2016 | -0.49% | -0.44% | 0.69x | 1.62x | €-2.56 Million |
| 2017 | 1.09% | 1.03% | 0.76x | 1.40x | €-2.58 Million |
| 2018 | 1.86% | 1.73% | 0.79x | 1.35x | €-2.38 Million |
| 2019 | 3.61% | 3.21% | 0.72x | 1.56x | €-1.94 Million |
| 2020 | 47.32% | 20.38% | 1.22x | 1.90x | €24.74 Million |
| 2021 | 61.98% | 27.19% | 1.42x | 1.60x | €87.22 Million |
| 2022 | 9.64% | 7.96% | 0.76x | 1.60x | €-582.59K |
| 2023 | -29.68% | -39.74% | 0.38x | 1.94x | €-49.39 Million |
| 2024 | -53.74% | -42.79% | 0.52x | 2.42x | €-51.36 Million |
Industry Comparison
This section compares Biosynex's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $16,728,413
- Average return on equity (ROE) among peers: -62.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biosynex (ALBIO) | €44.31 Million | 0.00% | 2.37x | $7.06 Million |
| Affluent Medical SAS (AFME) | $61.39 Million | -14.26% | 0.10x | $31.64 Million |
| Bluelinea SA (ALBLU) | $127.40K | -31.25% | 1.42x | $6.02 Million |
| Carmat (ALCAR) | $7.76 Million | -235.22% | 0.81x | $3.28 Million |
| Diagnostic Medical Systems SA (ALDMS) | $14.16 Million | -20.34% | 2.81x | $13.39 Million |
| Eurobio Scientific SA (ALERS) | $36.56 Million | 8.62% | 1.22x | $5.72 Million |
| Ikonisys SA (ALIKO) | $15.73 Million | -14.41% | 0.33x | $9.79 Million |
| Implanet SA (ALIMP) | $4.68 Million | -91.39% | 1.52x | $6.96 Million |
| Mediantechn (ALMDT) | $4.37 Million | -84.64% | 0.33x | $86.02 Million |
| Spineguard (ALSGD) | $5.77 Million | -78.70% | 0.48x | $5.69 Million |